Retinitis Pigmentosa (RP), an inherited disorder, although roughly affects 1 in 4,000 people, worldwide, results in the loss of peripheral vision in people suffering from this disease. While more than 200 causative mutations of RP have been previously discovered in more than 50 different genes, the molecular defect is distinguishable in just about half of the affected patients.
Despite the increasing prevalence of the RP, over the years, currently, no treatment is available to cure RP or arrest its progress. In several Health Systems, the overall management of the RP is difficult due to some unresolved important epidemiological issues for the lack of a shared and organized RP network.
However, International clinical trials, to find effective treatments, are showing great promise, and several organizations are determined to bring these promising trials to Pharmerging markets. Moreover, the researchers are doing their part by exploring exciting new approaches to stop the progression of vision deterioration. These include gene therapy, artificial retinas, stem cells, and many other innovative approaches.
To read more about Retinitis Pigmentosa visit: https://duphat.ae/gene-therapy-a-boon-for-retinitis-pigmentosa/
